[go: up one dir, main page]

MX2007012883A - Derivados de dihidrobenzofurano y usos de los mismos. - Google Patents

Derivados de dihidrobenzofurano y usos de los mismos.

Info

Publication number
MX2007012883A
MX2007012883A MX2007012883A MX2007012883A MX2007012883A MX 2007012883 A MX2007012883 A MX 2007012883A MX 2007012883 A MX2007012883 A MX 2007012883A MX 2007012883 A MX2007012883 A MX 2007012883A MX 2007012883 A MX2007012883 A MX 2007012883A
Authority
MX
Mexico
Prior art keywords
sup
compounds
formula
dihydrobenzofuran derivatives
agonists
Prior art date
Application number
MX2007012883A
Other languages
English (en)
Inventor
Gary Paul Stack
William Demaio
Christine Huselton
Jianyao Wang
Ronald Jordan
John Chuck Lem Erve
Rasmy Elsayed Talaat
Matthew John Hoffmann
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of MX2007012883A publication Critical patent/MX2007012883A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/81—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D307/85—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Reproductive Health (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Los compuestos de la formula (I) se describe aqui que son agonistas o agonistas parciales del subtipo 2C de los receptores de serotonina del cerebro de la Formula (I), o las sales de los mismos farmaceuticamente aceptables, en donde cada uno de R1, R2, R3, R4, Rx, Ry y n son como se definieron aqui. Tales compuestos, y las composiciones de los mismos, son utiles para el tratamiento de una variedad de trastornos del sistema nervioso central tales como la esquizofrenia. (ver formula I).
MX2007012883A 2005-04-22 2006-04-21 Derivados de dihidrobenzofurano y usos de los mismos. MX2007012883A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67415005P 2005-04-22 2005-04-22
PCT/US2006/015192 WO2006116150A1 (en) 2005-04-22 2006-04-21 Dihydrobenzofuran derivatives and uses thereof

Publications (1)

Publication Number Publication Date
MX2007012883A true MX2007012883A (es) 2007-12-10

Family

ID=36968764

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007012883A MX2007012883A (es) 2005-04-22 2006-04-21 Derivados de dihidrobenzofurano y usos de los mismos.

Country Status (13)

Country Link
US (1) US7402687B2 (es)
EP (1) EP1871755A1 (es)
JP (1) JP2008538572A (es)
CN (1) CN101175740A (es)
AR (1) AR056980A1 (es)
AU (1) AU2006239920A1 (es)
BR (1) BRPI0608475A2 (es)
CA (1) CA2604916A1 (es)
GT (1) GT200600164A (es)
MX (1) MX2007012883A (es)
PE (1) PE20061298A1 (es)
TW (1) TW200718692A (es)
WO (1) WO2006116150A1 (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0210397D0 (en) * 2002-05-07 2002-06-12 Ferring Bv Pharmaceutical formulations
US20050261347A1 (en) * 2003-10-24 2005-11-24 Wyeth Dihydrobenzofuranyl alkanamine derivatives and methods for using same
US7435837B2 (en) * 2003-10-24 2008-10-14 Wyeth Dihydrobenzofuranyl alkanamine derivatives and methods for using same
GT200500296A (es) * 2004-10-21 2006-10-02 Sintesis asimetrica de derivados del dehidrobenzofurano
GT200500297A (es) * 2004-10-21 2006-10-27 Sintesis asimetrica de dehidrobenzofuranos sustituidos
PE20070093A1 (es) * 2005-04-22 2007-02-07 Wyeth Corp Derivados dihidrobenzofuranos como moduladores del receptor 5-ht2c
AU2006239910A1 (en) * 2005-04-22 2006-11-02 Wyeth Dihydrobenzofuran derivatives and uses thereof
AU2006239918A1 (en) * 2005-04-22 2006-11-02 Wyeth New therapeutic combianations for the treatment or prevention of depression
AU2006239922A1 (en) * 2005-04-22 2006-11-02 Wyeth Benzofuranyl alkanamine derivatives and uses thereof as 5-HT2c agonists
CA2605580A1 (en) * 2005-04-22 2006-11-02 Wyeth Benzodioxane and benzodioxolane derivatives and uses thereof
JP2008538582A (ja) * 2005-04-22 2008-10-30 ワイス 精神病性障害の治療または予防のための新規の治療的組み合わせ
AU2006239943A1 (en) * 2005-04-22 2006-11-02 Wyeth Treatment of pain
GT200600164A (es) 2005-04-22 2007-03-14 Derivados de dihidrobenzofuranos y usos de los mismos
WO2006116169A2 (en) * 2005-04-24 2006-11-02 Wyeth Methods for modulating bladder function
TW200806287A (en) * 2006-03-24 2008-02-01 Wyeth Corp Methods for treating cognitive and other disorders
WO2007132841A1 (ja) 2006-05-16 2007-11-22 Takeda Pharmaceutical Company Limited 縮合複素環化合物およびその用途
US8241357B2 (en) * 2007-04-25 2012-08-14 Jmea Corporation Prosthesis with a selectively applied bone growth promoting agent
US8399410B2 (en) 2007-08-06 2013-03-19 Allergan, Inc. Methods and devices for desmopressin drug delivery
JP5520051B2 (ja) 2007-11-15 2014-06-11 武田薬品工業株式会社 縮合ピリジン誘導体およびその用途
JP2010043063A (ja) 2008-05-09 2010-02-25 Agency For Science Technology & Research 川崎病の診断及び治療
US11963995B2 (en) 2008-05-21 2024-04-23 Ferring B.V. Methods comprising desmopressin
SI3225250T1 (sl) 2008-05-21 2019-11-29 Ferring Bv Orodisperzibilen dezmopresin za podaljšanje začetnega obdobja spanja, ki ga ne moti nokturija
US20100286045A1 (en) 2008-05-21 2010-11-11 Bjarke Mirner Klein Methods comprising desmopressin
CN101712879B (zh) * 2009-09-23 2013-03-20 中国科学技术大学 制备2,3-二氢苯并呋喃和生物油的方法及其专用装置
WO2011071136A1 (ja) 2009-12-11 2011-06-16 アステラス製薬株式会社 線維筋痛症治療剤
CN102250048B (zh) * 2011-06-03 2013-06-05 浙江工业大学 2-苯硒基甲基-2,3-二氢苯并呋喃及其制备与应用
WO2015066344A1 (en) 2013-11-01 2015-05-07 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists and compositions and methods of use
WO2019131902A1 (ja) 2017-12-27 2019-07-04 武田薬品工業株式会社 腹圧性尿失禁および便失禁の治療薬
CN117924208A (zh) 2018-01-19 2024-04-26 赛特凯恩蒂克公司 作为心肌节抑制剂的二氢苯并呋喃和茚类似物
JP7438148B2 (ja) 2018-06-26 2024-02-26 サイトキネティックス， インコーポレイテッド 心臓サルコメア阻害剤
EP3814343B1 (en) 2018-06-26 2023-01-11 Cytokinetics, Inc. Cardiac sarcomere inhibitors
WO2020087031A1 (en) 2018-10-26 2020-04-30 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
US11559502B2 (en) 2019-08-26 2023-01-24 Period Pill Bv Treatment of menstrual cycle-induced symptoms
EP3878447A1 (en) 2020-03-11 2021-09-15 InterAx Biotech AG Beta adrenergic receptor antagonists
WO2022187501A1 (en) 2021-03-04 2022-09-09 Cytokinetics, Inc. Cardiac sarcomere inhibitors

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2554736A (en) 1951-05-29 Tertiary aminoalkyl-iminodibenzyls
GB1422263A (en) 1973-01-30 1976-01-21 Ferrosan As 4-phenyl-piperidine compounds
US4314081A (en) 1974-01-10 1982-02-02 Eli Lilly And Company Arloxyphenylpropylamines
NL7503310A (nl) 1975-03-20 1976-09-22 Philips Nv Verbindingen met antidepressieve werking.
GB1526331A (en) 1976-01-14 1978-09-27 Kefalas As Phthalanes
US4210754A (en) 1977-02-01 1980-07-01 Hoffmann-La Roche Inc. Morpholino containing benzamides
IL56369A (en) 1978-01-20 1984-05-31 Erba Farmitalia Alpha-phenoxybenzyl propanolamine derivatives,their preparation and pharmaceutical compositions comprising them
US4536518A (en) 1979-11-01 1985-08-20 Pfizer Inc. Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine
FR2508035A1 (fr) 1981-06-23 1982-12-24 Fabre Sa Pierre Derives d'aryl-1-aminomethyl-2 cyclopropanes carboxamides (z), leur preparation et leur application en tant que medicaments utiles dans le traitement des troubles du systeme nerveux central
US4535186A (en) 1983-04-19 1985-08-13 American Home Products Corporation 2-Phenyl-2-(1-hydroxycycloalkyl or 1-hydroxycycloalk-2-enyl)ethylamine derivatives
GB8814057D0 (en) 1988-06-14 1988-07-20 Lundbeck & Co As H New enantiomers & their isolation
DE4200259A1 (de) 1992-01-08 1993-07-15 Asta Medica Ag Neue 1,2,4-triaminobenzol-derivate und verfahren zu deren herstellung
KR0173172B1 (ko) 1992-12-17 1999-02-01 알렌 제이. 스피겔 Crf 길항제로서의 피롤로피리미딘
TW370529B (en) 1992-12-17 1999-09-21 Pfizer Pyrazolopyrimidines
BR9307659A (pt) 1992-12-17 1999-06-29 Pfizer Pirazóis e pirazolopirimidinas tendo atividade antagonista crf
PT1738753E (pt) 1993-06-28 2008-06-19 Wyeth Corp Novos tratamentos utilizando derivados de fenetilamina
US5705646A (en) 1993-09-30 1998-01-06 Pfizer Inc. Substituted pyrazoles as CRF antagonists
US5668145A (en) 1993-11-12 1997-09-16 Pfizer Inc. Amino-substituted pyrazoles having CRF antagonistic activity
CN100384825C (zh) 1994-06-15 2008-04-30 大塚制药株式会社 苯并杂环衍生物
US5565483A (en) 1995-06-07 1996-10-15 Bristol-Myers Squibb Company 3-substituted oxindole derivatives as potassium channel modulators
TW359669B (en) 1995-12-15 1999-06-01 Otsuka Pharma Co Ltd Benzazepine derivatives
US6274171B1 (en) 1996-03-25 2001-08-14 American Home Products Corporation Extended release formulation of venlafaxine hydrochloride
US6194407B1 (en) 1997-07-30 2001-02-27 American Home Products Corporation Tricyclic pyrido vasopressin agonists
US6090803A (en) 1998-07-24 2000-07-18 American Home Products Corporation Tricyclic vasopressin agonists
CA2361516A1 (en) * 1999-01-27 2000-08-03 Jeffrey Thomas Mullaney Aminoalkylbenzofurans as serotonin (5-ht(2c)) agonists
US7045545B1 (en) 1999-01-27 2006-05-16 Eli Lilly And Company Aminoalkylbenzofurans as serotonin (5-HT(2c)) agonists
US20020183395A1 (en) 2001-04-04 2002-12-05 Wyeth Methods for treating hyperactive gastric motility
US20040235856A1 (en) 2003-04-25 2004-11-25 Pfizer Inc Treatment of incontinence
US7435837B2 (en) * 2003-10-24 2008-10-14 Wyeth Dihydrobenzofuranyl alkanamine derivatives and methods for using same
US7728155B2 (en) 2003-10-24 2010-06-01 Wyeth Llc Dihydrobenzofuranyl alkanamines and methods for using same as cns agents
US20050261347A1 (en) 2003-10-24 2005-11-24 Wyeth Dihydrobenzofuranyl alkanamine derivatives and methods for using same
WO2006000902A1 (en) 2004-06-25 2006-01-05 Pfizer Products Inc. Dihydrobenzofuran compounds and uses thereof
GT200500297A (es) 2004-10-21 2006-10-27 Sintesis asimetrica de dehidrobenzofuranos sustituidos
GT200500296A (es) 2004-10-21 2006-10-02 Sintesis asimetrica de derivados del dehidrobenzofurano
JP2008538582A (ja) 2005-04-22 2008-10-30 ワイス 精神病性障害の治療または予防のための新規の治療的組み合わせ
GT200600164A (es) 2005-04-22 2007-03-14 Derivados de dihidrobenzofuranos y usos de los mismos
PE20070093A1 (es) 2005-04-22 2007-02-07 Wyeth Corp Derivados dihidrobenzofuranos como moduladores del receptor 5-ht2c
AU2006239910A1 (en) 2005-04-22 2006-11-02 Wyeth Dihydrobenzofuran derivatives and uses thereof
BRPI0610785A2 (pt) 2005-04-22 2016-09-13 Wyeth Corp polimorfo cristalino, processo para preparar o mesmo, forma cristalina, composição, e, métodos para tratar uma doença, distúrbios, e uma condição
JP2008538766A (ja) 2005-04-22 2008-11-06 ワイス 薬物乱用の処置
TW200716595A (en) 2005-04-22 2007-05-01 Wyeth Corp Chromane and chromene derivatives and uses thereof
CA2605580A1 (en) 2005-04-22 2006-11-02 Wyeth Benzodioxane and benzodioxolane derivatives and uses thereof
AU2006239922A1 (en) 2005-04-22 2006-11-02 Wyeth Benzofuranyl alkanamine derivatives and uses thereof as 5-HT2c agonists
AU2006239918A1 (en) 2005-04-22 2006-11-02 Wyeth New therapeutic combianations for the treatment or prevention of depression
AU2006239943A1 (en) 2005-04-22 2006-11-02 Wyeth Treatment of pain
WO2006116169A2 (en) 2005-04-24 2006-11-02 Wyeth Methods for modulating bladder function

Also Published As

Publication number Publication date
US7402687B2 (en) 2008-07-22
US20060241176A1 (en) 2006-10-26
TW200718692A (en) 2007-05-16
WO2006116150A1 (en) 2006-11-02
JP2008538572A (ja) 2008-10-30
PE20061298A1 (es) 2006-12-24
AU2006239920A1 (en) 2006-11-02
EP1871755A1 (en) 2008-01-02
AR056980A1 (es) 2007-11-07
GT200600164A (es) 2007-03-14
CN101175740A (zh) 2008-05-07
CA2604916A1 (en) 2006-11-02
BRPI0608475A2 (pt) 2010-01-05

Similar Documents

Publication Publication Date Title
MX2007012883A (es) Derivados de dihidrobenzofurano y usos de los mismos.
MX2007012936A (es) Derivados de dihidrobenzofurano y usos de los mismos.
TW200720266A (en) Benzodioxane and benzodioxolan derivatives and uses thereof
MX2007013021A (es) Derivados de benzofuranil-alcanamina y usos de los mismos como agonistas de 5-ht2c.
TW200716595A (en) Chromane and chromene derivatives and uses thereof
NO20062139L (no) Dihydrobenzofuranyl-alkanaminderivater som 5HT2C-agonister
MXPA05009359A (es) Tetrahidroisoquinolinas 2,5- y 2,6 substituidas para uso como moduladores 5-ht6.
TN2009000180A1 (en) NOVEL 1,4-BENZOTHIEPIN-l,1-DIOXIDE DERIVATIVES WHICH ARE SUBSTITUTED WITH BENZYL GROUPS, METHOD FOR PRODUCING DRUGS CONTAINING SAID COMPOUNDS AND USE THEREOF
DE602004009200D1 (de) Tetrahydrochinazolinderivate als cfr-antagonisten
EA200601194A1 (ru) Новые производные бензофурана, используемые для профилактики или лечения нарушений, связанных с 5-ht-рецептором
WO2008052075A3 (en) Benzoxazine derivatives and uses thereof
IL186777A0 (en) (3,4-dihydro-quinazolin-2-yl) - (2-aryloxy-ethyl) - amines having an activity on the 5 - ht receptor
BRPI0607532A2 (pt) derivados de alcanamina de diidrobenzofuranila como agonistas de 5ht2c
WO2008020306A3 (en) Isoindole derivatives
MY145609A (en) Piperidin-4-yl-pyridazin-3-ylamine derivatives as fast dissociating dopamine 2 receptor antagonists
MX2009011415A (es) Derivados de 4-alcoxipiridazina como antagonistas del receptor de dopamina 2 de rapida disociacion.
MX2007011847A (es) Derivados de pirimidindiona como antagonistas del receptor de procineticina 2.
DK1636239T3 (da) Indolderivater med en forbedret antipsykotisk aktivitet
EA200501148A1 (ru) Пиридилоксиметильные и бензизоксазольные азабициклические производные
WO2008052088A8 (en) Chromane derivatives, synthesis thereof, and intermediates thereto
WO2006050007A3 (en) Substituted indolizines and derivatives as cns agents
WO2008052078A3 (en) Benzoxathiine and benzoxathiole derivatives and uses thereof
ATE409179T1 (de) Tetralin- und indanderivate und deren anwendungen als 5-ht-antagonisten
MX2009005242A (es) Derivados de 3-(hetero)arilisoquinolinamida sustituida en posición 5, 6 o 7 y uso terapeutico del mismo.
IL188927A0 (en) Aryloxy quinolines and uses thereof as 5-ht6 modulators

Legal Events

Date Code Title Description
FA Abandonment or withdrawal